SARS-CoV2 might conduce to rapid respiratory complications challenging healthcare systems worldwide. Immunological mechanisms associated to SARS-CoV2 infection are complex and not yet clearly elucidated. Arguments are in favour of a well host-adapted virus. Here I draw a systemic immunological representation linking actual SARS-CoV2 infection literature that hopefully might guide healthcare decisions to treat COVID-19. I suggest HLA-G and HLA-E, non classical HLA class I molecules, in the core of COVID-19 complications. These molecules are powerful in immune tolerance and might inhibit/suppress immune cells functions during SARS-CoV2 infection promoting virus subversion. Dosing soluble forms of these molecules in COVID-19 patients’ plasma might help the identification of critical cases. I recommend also developing new SARS-CoV2 therapies based on the use of HLA-G and HLA-E or their specific receptors antibodies in combination with FDA approved therapeutics to combat efficiently COVID-19.

SARS-CoV2 可能会导致快速的呼吸道并发症，给全球医疗保健系统带来挑战。与 SARS-CoV2 感染相关的免疫机制很复杂，尚未明确阐明。争论有利于宿主适应良好的病毒。在这里，我绘制了一个系统免疫学表示，将实际的 SARS-CoV2 感染文献联系起来，希望可以指导治疗 COVID-19 的医疗保健决策。我建议 HLA-G 和 HLA-E，非经典 HLA I 类分子，是 COVID-19 并发症的核心。这些分子具有强大的免疫耐受性，可能会在 SARS-CoV2 感染期间抑制/压制免疫细胞功能，从而促进病毒颠覆。在 COVID-19 患者血浆中添加这些分子的可溶形式可能有助于识别危重病例。我还建议开发基于 HLA-G 和 HLA-E 或其特定受体抗体的新 SARS-CoV2 疗法，并与 FDA 批准的疗法相结合，以有效对抗 COVID-19。